Emerging analyses on retatrutides, a dual activator for GLP-1 and glucose-dependent insulinotropic polypeptide, indicate promising results in managing excess body fat and type 2 glucose intolerance. Early evidence from clinical assessments reveal considerable reductions in body weight and enhance